Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

17.31 +0.04 (+0.23%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025

From Summit Therapeutics Inc.

Via Business Wire

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? ↗

May 11, 2025

The worst performing large-cap stocks last week: ARGENX, VRTX, SMMT, MMYT, REGN, RKT, BNTX, AFRM, FNF, LLY, AUR, DASH. Any in your portfolio?

Via Benzinga

Can Summit Therapeutics Stock Double Your Money? ↗

May 07, 2025

Via The Motley Fool

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗

May 04, 2025

Top performing large-cap stocks in the last week: DUOL, CRWV, THC, CARR, SMMT, AUR, ANET, TT, DXCM, XPO. Most had positive financial results and raised guidance.

Via Benzinga

This Soaring Stock Just Delivered More Good News. Time to Buy? ↗

May 02, 2025

Via The Motley Fool

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 01, 2025

From Summit Therapeutics Inc.

Via Business Wire

9 Health Care Stocks Whale Activity In Today's Session ↗

April 28, 2025

Via Benzinga

Why Is Summit Therapeutics Stock Trading Higher On Monday? ↗

April 28, 2025

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial.

Via Benzinga

Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗

April 28, 2025

Via Benzinga

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back ↗

April 26, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today ↗

April 25, 2025

Via The Motley Fool

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

April 25, 2025

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Via Chartmill

What's Going On With Summit Therapeutics Stock On Friday? ↗

April 25, 2025

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials.

Via Benzinga

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

April 25, 2025

From Summit Therapeutics Inc.

Via Business Wire

Top stock movements in today's session. ↗

April 25, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic ↗

April 25, 2025

The company’s lead candidate, ivonescimab, aimed at treating certain cancers, was discovered by Akeso and is currently in multiple late-stage clinical trials.

Via Stocktwits

Topics Artificial Intelligence

12 Health Care Stocks Moving In Friday's Intraday Session ↗

April 25, 2025

Via Benzinga

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

April 24, 2025

From Summit Therapeutics Inc.

Via Business Wire

Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial ↗

April 23, 2025

The study was conducted across multiple centers in China, comparing ivonescimab plus chemotherapy against tislelizumab (marketed as Tevimbra by BeiGene) plus chemotherapy.

Via Stocktwits

Why Summit Therapeutics Rocketed Double-Digits Today ↗

April 23, 2025

Via The Motley Fool

Topics World Trade

Why Is Summit Therapeutics Stock Soaring On Wednesday? ↗

April 23, 2025

Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.

Via Benzinga

BioNTech Surges On Summit's Coattails. But Can They Take On Merck? ↗

April 23, 2025

BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.

Via Investor's Business Daily

Amphenol Posts Better-Than-Expected Results, Joins SAP, Tesla, Pegasystems And Other Big Stocks Moving Higher On Wednesday ↗

April 23, 2025

Via Benzinga

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

April 23, 2025

From Summit Therapeutics Inc.

Via Business Wire

This Company's Co-CEOs Just Bought More Shares. Should You? ↗

April 23, 2025

Via The Motley Fool

In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio? ↗

April 20, 2025

Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.

Via Benzinga

Top 3 Health Care Stocks You May Want To Dump This Quarter ↗

April 15, 2025

Via Benzinga

Top 3 Biotech Stocks That Got Retail Street Buzzing Last Week: SMMT, PTN, RXRX ↗

April 13, 2025

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

Via Stocktwits

Topics Animal Testing

April 13, 2025

Last week's top performers: SMMT, HMY, AU, CVNA, HOOD, NEM, AVGO, GFI, KGC, CEG. Are they in your portfolio? #stockmarket #investing

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.